Is azathioprine harmful to chronic viral hepatitis in renal transplantation? A long-term study on azathioprine withdrawal
| Autor: | de Paula Fj, Ianhez Le, da Fonseca Ja, Elias David-Neto, William C. Nahas, Emil Sabbaga |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Azathioprine Gastroenterology Drug Administration Schedule Liver disease Hepatitis B Chronic Postoperative Complications Cholestasis Liver Function Tests Internal medicine medicine Humans Retrospective Studies Hepatitis Transplantation business.industry Hepatitis C Hepatitis C Chronic medicine.disease Kidney Transplantation Survival Rate Liver Immunology Disease Progression Surgery Female Viral disease business Viral hepatitis Immunosuppressive Agents medicine.drug Follow-Up Studies |
| Zdroj: | Transplantation proceedings. 31(1-2) |
| ISSN: | 0041-1345 |
| Popis: | CHRONIC viral hepatitis represents one major morbidity factor in renal transplantation because the incidence of hepatitis C reaches 30% of the patients. Azathioprine (AZA) has been a major immunosuppressive agent for decades. Among the AZA side effects, AZA hepatitis is one of the most common, presenting with an increase in the serum liver enzymes due to hepatocellular necrosis and sometimes increased bilirubin serum levels due to intrahepatic cholestasis. The AZA side effects are now recognized as occurring almost exclusively in patients with viral liver disease, either hepatitis C or B. There is a concern that the use of AZA can precipitate the progression of liver disease and patient morbidity and mortality. We report here the results of a single-center retrospective study comparing AZA withdrawal with dose reduction only, on the progression of liver disease and patient survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect